Abbott LaboratoriesABT is slated to report second-quarter 2025 results on July 17, before the opening bell. The company ...

The device focuses on examining sonoporation-based drug delivery that involves ultrasound-based treatment with microbubbles.

The upcoming report from Abbott (ABT) is expected to reveal quarterly earnings of $1.25 per share, indicating an increase of 9.7% compared to the year-ago period. Analysts forecast revenues of $11.07 ...

The global Brain Pacemaker Market represents a rapidly expanding segment of the medical device industry, valued at USD 3.66 ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

This work presents a modular, light-weight head-borne neuromodulation platform that achieves low-power wireless neuromodulation and allows real-time programmability of the stimulation parameters such ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...